Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.4053
-0.0418 (-9.35%)
At close: Oct 9, 2026, 4:00 PM EDT
0.4200
+0.0147 (3.63%)
After-hours: Oct 9, 2026, 7:52 PM EDT
Humacyte Revenue
Humacyte had revenue of $406.00K in the quarter ending June 30, 2026, with 34.88% growth. This brings the company's revenue in the last twelve months to $2.12M, up 159.29% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M. That makes Humacyte the 42,217th largest company in the world by revenue and 5,733rd in the United States.
Revenue (ttm)
$2.12M
Revenue Growth
+159.29%
P/S Ratio
53.08
Revenue / Employee
$11,527
Employees
184
Market Cap
112.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 21.48M |
| Coya Therapeutics | 8.02M |
| Rani Therapeutics Holdings | 4.88M |
| Milestone Pharmaceuticals | 2.34M |
| Inovio Pharmaceuticals | 65.34K |
| Genelux | 8.00K |
HUMA News
- 3 days ago - Humacyte initiated with an Equal Weight at Barclays - TheFly
- 12 days ago - Humacyte announces addition of Coward, Kuznik to board - TheFly
- 12 days ago - Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik - GlobeNewsWire
- 23 days ago - Humacyte Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Humacyte announces FDA extension of expiration dating period for Symvess - TheFly
- 4 weeks ago - Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months - GlobeNewsWire
- 5 weeks ago - Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA - Business Wire